RT Journal Article
T1 Impact of Pre-Treatment Serum Ferritin on Response and Survival in Myelodysplastic Syndromes Treated With Azacytidine: A Multivariate Analysis
A1 Moreno Carrasco, Gloria
A1 Ortiz-Flores, Rodolfo
A1 García Delgado, Regina
A1 Cidoncha Morcillo, Borja
A1 Rosell-Mas, Ana Isabel
A1 Díaz Canales, Dana
A1 Rodríguez-González, María
A1 Carrasco Gomariz, Manuel
A1 Escamilla-Sánchez, Alejandro
K1 Síndromes mielodisplásicos
K1 Marcadores bioquímicos
K1 Supervivencia
K1 Pronóstico médico
AB Background: Myelodysplastic syndromes (MDS) encompass a heterogeneous group of haematological neoplasms characterizedby ineffective haematopoiesis and a variable risk of transformation to acute myeloid leukaemia (AML). Elevated serum ferritin(SF), a marker of iron overload (IO), has been linked to poorer outcomes in MDS. However, the impact of pre-treatment SF levelson azacytidine (AZA) response and survival outcomes remains unclear.Methods: This retrospective cohort study included patients with World Health Organization- defined MDS or AML with20%–30% bone marrow blasts treated with AZA at the Virgen de la Victoria University Hospital (Málaga, Spain) from 2007onwards. Patients were stratified into three groups based on pre-treatment SF levels: < 500 ng/mL, 500–1000 ng/mL and> 1000 ng/mL. Logistic regression and Kaplan–Meier methods were used to analyse overall response (OR) and overall sur-vival (OS).Results: Among 240 patients, 190 with available SF data were analysed. Patients with SF > 1000 ng/mL showed significantlylower OR (24.2%) and shorter OS (median: 10.1 months) compared to those with SF < 500 ng/mL (OR: 71.4%, OS: 18.2 months)and 500–1000 ng/mL (OR: 82.6%, OS: 20.5 months) (p < 0.0001 for OR, p = 0.001 for OS). Multivariate analysis confirmed elevatedSF as an independent predictor of poorer outcomes.Conclusions: Elevated pre-treatment SF levels are strongly associated with reduced response and survival in patients with MDSor AML treated with AZA. Early IO management, such as iron chelation, may improve treatment outcomes.
PB Wiley Gold
YR 2025
FD 2025
LK https://hdl.handle.net/10630/40023
UL https://hdl.handle.net/10630/40023
LA eng
NO Carrasco GM, Flores RMO, Delgado RG, Morcillo BC, Rosell Mas AI, Díaz Canales D, González MR, Gomariz MC, Escamilla-Sánchez A. Impact of Pre-Treatment Serum Ferritin on Response and Survival in Myelodysplastic Syndromes Treated With Azacytidine: A Multivariate Analysis. Cancer Med. 2025 Aug;14(15):e71127. doi: 10.1002/cam4.71127. PMID: 40755125; PMCID: PMC12319231.
NO Hospital Universitario Virgen de la Victoria
DS RIUMA. Repositorio Institucional de la Universidad de Málaga
RD 20 ene 2026